Compare Eli Lilly And Co (LLY) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs PepsiCo, Inc. — how do they compare? Eli Lilly And Co trades at $1,159.57 (market cap $1.02T), while PepsiCo, Inc. trades at $134.58 (market cap $184.89B). The key difference: Eli Lilly And Co is far larger — about 5.5× PepsiCo, Inc.'s market cap, and PepsiCo, Inc. pays the higher dividend (4.37%). Which is the better fit depends on your goals.
| LLY | PEP | |
|---|---|---|
Market Cap | $1.02T | $184.89B |
Sector | Health | Consumer Staples |
52-Week High | $1.24K | $170.44 |
52-Week Low | $625.65 | $135.40 |
Enterprise Value | $1.06T | $227.39B |
Dividend Yield | 0.6% | 4.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
PepsiCo (PEP) trades at $134.62, down 1.82% over the past day, with a bearish technical signal from moving averages. The company reported revenue of $93.93B in 2025, with a net income margin of 10.78% and a P/E ratio of 17.75. Recent news highlights price cuts on snacks like Doritos to address consumer pushback, while Q3 2026 earnings are anticipated at $2.32 EPS. Analyst consensus is a 'Hold' with a $158.50 price target, suggesting moderate upside from current levels.
The outlook for PEP hinges on execution of its North American turnaround and margin expansion initiatives. Risks include competitive pressures and sensitivity to consumer spending. With strong cash flow generation and a dividend yield near 4%, the stock offers value for income-focused investors, though near-term volatility may persist amid earnings uncertainty and market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
